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Background
Tuberculosis (TB) is the second leading cause of death by
infectious disease worldwide. About 1.4 million people die
of TB each year. Parenterally administered Mycobacterium
bovis BCG vaccine confers only limited immune protec-
tion from pulmonary tuberculosis in humans. There is a
need for developing effective boosting vaccination strate-
gies. AdAg85A adenovirus, a new promising tuberculosis
vaccine candidate, has been studied with mouse, guinea
pig, goat and cow animal models, and was shown to be
effective against Mycobacterium tuberculosis (Mtb) infec-
tion [1]. A phase I trial on Ad5Ag85A adenovirus was also
conducted, which demonstrated that AdAg85A adenovirus
was safe and highly immunogenic [2].
To further evaluate the efficacy of this vaccine and
reduce the cost of this promising vaccine candidate, a
feasible and cost-effective large-scale cell culture pro-
duction process had to be developed for manufacturing
large quantities of AdAg85A adenovirus required for
further clinical trials. Furthermore, the process had to
be designed to meet all requirements for industrializa-
tion and commercialization of this vaccine candidate.
Here we report our study on optimization of cell culture
conditions, scale up of AdAg85A adenovirus production
in 60L bioreactor and purification of the AdAg85A ade-
novirus at different scales. The optimized conditions for
AdAg85A adenovirus production and purification were
transferred to a GMP facility for manufacturing of
AdAg85A adenovirus for further clinical trials.
Materials and methods
Four commercial serum-free cell culture media
(SFM4HEK-293 and SFM4Transfx-293 from HyClone;
Adenovirus Expression Medium (AEM) and CD 293
from Life Technologies), were evaluated for supporting
the growth of HEK293SF-3F6 cell in suspension and also
for the production of AdAg85a adenovirus in 125 mL
shake flask cultures under various experimental condi-
tions. The production of the AdAg85A adenovirus was
then scaled up to 3L controlled bioreactor under the
optimized conditions obtained from the shake flask
experiment, further validated in a 60L bioreactor.
Purification of the AdAg85A adenovirus was accom-
plished through many different steps. Some of the critical
steps include cell lysis, benzonase® treatment, Q-Sepharose
HP anion exchange chromatography for capture of adeno-
virus/purification, Capto Core 700 multimodal chromato-
graphy for polishing, concentration and diafiltration into
formulation buffer. The purification processes were also
scaled up from 3L to 60 L production scale.
Results
Three among four media supported growth of HEK293SF-
3F6up to 4x106 cells/mL, however, the production yield of
AdAg85A in the three media varied considerably. More
than one log difference in viral titres has been observed as
shown in Figure 1. Although CD293 medium did not sup-
port the cell growth, however, the virus production was
further improved by more than two folds when the cells
were grown in SFM4HEK293 medium to respective cell
density of 2x106 cells/mL and 4x106 cells/mL, and then
diluted with the same amount of CD 293 medium before
the virus infection. This result clearly indicates that
HEK293 has different nutritional requirements during the
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phases of cell growth and virus production. Highest titer
(5x1010 total viral particles/mL) of AdAg85A adenovirus
was achieved by growing HEK293SF-3F6 cell in one of the
above 3 media to a cell density of about 4x106 cells/mL,
and then diluting the culture with the same of CD293
before the virus infection. These optimized culture condi-
tions eliminated the medium exchange step and contami-
nation risk associated with, and also contributed to
reducing the cost of goods.
The production of AdAg85A adenovirus was success-
fully scaled up to 3L bioreactor, and then validated in
60L bioreactor production. Experimental result showed
that configuration of bioreactor might significantly affect
the yield of AdAg85A adenovirus
Purification of AdAg85A adenovirus was successfully
scaled up to 60L scale production. Experimental data
revealed that an additional step of freeze-thaw follow-
ing the cell lysis helped the release of AdAg85A ade-
novirus from the cell and thus improved the virus
recovery. Recovery rate of total viral particles was
more than 60% after anion exchange and Capto Core
700 multimodal chromatography for polishingstep
(Table 1). However, experimental result also showed
that it was a challenge to use a stir cell system to
further concentrate the flow through (with 2x1012
viral particles/mL) from Capto Core 700 multimodal
chromatography step.
More than 99% of host cell protein was removed dur-
ing the purification process. Total protein concentration
was 260 µg/mL in the purified product. Purity of the
purified product was equal to that of the ATCC VR-
1516 Ad5 standard by SDS-Page, silver stain analysis.
The ratio of infectious viral particles to total viral parti-
cles in the purified material was in a range of 10%.
Endotoxin concentration of the purified material was
lower than 0.10 EU/mL.
Conclusions
A high yield bioprocess was successfully developed, and
scaled up to 60L scale for production of AdAg85A ade-
novirus using HEK293SF 3F6 cell and serum-free media.
The developed downstream process efficiently purified
the AdAg85A produced at different scales and with
acceptable virus recovery.
Figure 1 Screening of culture media and optimization of culture conditions for adenovirus production (A: total viral particle
concentration; B: infectious viral particle concentration). The cells grown in the above 3 media were infected at 1x106 cells/mL with or
without medium replacement before infection.
Table 1. Recovery of total and infectious viral particles and removal of total proteins in purification steps in a 3 L
scale run
Samples Total viral particles Recovery Total infectious particles Recovery Total proteins (mg) Recovery
Harvest broth 7.1 × 1013 100% 6.5 × 1012 100% 1112 100%
10X conc. lysate 5.1 × 1013 72% 5.7 × 1012 88% 993 89%
Q-Seph HP feed 7.2 × 1013 101% 5.0 × 1012 77% 882 79%
Q-Seph HP
1M NaCl peak
5.3 × 1013 75% 3.8 × 1012 59% 68 6%
Capto Core 700 flowthrough 4.3 × 1013 61% 3.2 × 1012 49% 11 1%
Final product 2.0 × 1013 28% 2.6 × 1012 40% 4 0.4%
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